JavaScript is disabled for your browser. Some features of this site may not work without it.
Statistics
Total Visits
| Views | |
|---|---|
| Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial | 168 |
Total Visits Per Month
| November 2024 | December 2024 | January 2025 | February 2025 | March 2025 | April 2025 | May 2025 | |
|---|---|---|---|---|---|---|---|
| Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial | 4 | 5 | 5 | 9 | 9 | 14 | 1 |
Top country views
| Views |
|---|
Top cities views
| Views |
|---|
